- Home
- AVPT vs ELVN Comparison
AVPT vs ELVN Comparison
Compare AVPT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVPT | ELVN |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | 2934 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AVPT | ELVN |
|---|---|---|
| Price | $9.80 | $43.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $16.64 | ★ $43.40 |
| AVG Volume (30 Days) | 1.4M | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.00 | N/A |
| Revenue Next Year | $19.63 | N/A |
| P/E Ratio | $1,348.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.24 | $13.30 |
| 52 Week High | $20.25 | $43.35 |
Technical Indicators
Market Signals| Indicator | AVPT | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 72.78 |
| Support Level | $9.24 | $18.04 |
| Resistance Level | $14.33 | N/A |
| Average True Range (ATR) | 0.38 | 2.87 |
| MACD | 0.04 | 0.81 |
| Stochastic Oscillator | 39.45 | 88.64 |
Price Performance
Historical ComparisonAbout AVPT AvePoint Inc.
AvePoint Inc provides customizable solutions to optimize SaaS operations, enable secure collaboration, and accelerate digital transformation across technologies and industries. Its Confidence Platform delivers a comprehensive set of cloud-based solutions enabling IT operations, development operations, and cybersecurity professionals to monitor and secure the digital workplace using SaaS tools.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.